The European LeukemiaNet is a publicly funded research network of excellence. Goal is cure of leukemia by
integration of European leukemia research and spread of excellence. The website delivers
information for physicians, patients (e.g. patient organisations in Europe), ongoing clinical trials and
further information about the disease. You can get information about the European LeukemiaNet in
various european languages. The European LeukemiaNet is
funded by the 6th Framework Program of the European Community.
Right in time for the annual symposium, we are pleased to present the 12th Information Letter of the European LeukemiaNet. In this issue: results from the PROMYSE APL registry, new therapies and the role of TP53 alterations in CLL, ELTS-score for CML, the new EU-regulation on clinical trials, MDS-RIGHT, and many more.
194 Participating Centers in 39 Countries (1000 Researchers and Associates) are cooperating in the European Leukemia Net. The objective is to integrate the 108 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, CMPD), their 105 interdisciplinary partners (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a cooperative network for advancements in leukemia related research and health care (data updated July 2013).